Kiora Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results beat consensus on the bottom line, with a GAAP net loss of $2.08M vs. $2.84M expected, and EPS of -$0.34 vs. -$0.62 expected. While revenue remains at zero (in-line with expectations for this clinical-stage firm), the variance was driven by lower-than-anticipated operating expenses and sustained collaboration credits from partner Théa Open Innovation. Management confirmed a robust cash runway extending into late 2028, supported by a $4.9M private placement in April 2026.